![PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A](https://www.researchgate.net/profile/Katarina-Kovacevic/publication/363592628/figure/tbl1/AS:11431281087054351@1664444637401/Demographic-and-Clinical-Characteristics-at-Baseline_Q320.jpg)
PDF) von Willebrand Factor-binding aptamer rondoraptivon pegol as treatment for severe and non-severe hemophilia A
![Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice](https://www.jhoponline.com/images/supplements/2022/TLG2245/table.png)
Sacituzumab Govitecan Moves to Second-Line Therapy for Metastatic Triple-Negative Breast Cancer: Applying the Lessons from Clinical Trials to Clinical Practice
![Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis](https://www.rpthjournal.org/cms/attachment/dbe8be26-51b2-4fab-9f13-0ee153963099/rth212760-fig-0001-m_lrg.jpg)
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
![PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A](https://www.researchgate.net/publication/304814489/figure/fig3/AS:381313644285954@1467923665257/ABRs-for-BAY-81-8973-1-year-vs-turoctocog-alfa-Notes-P005-Data-from-Lentz-et-al_Q320.jpg)
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis](https://www.rpthjournal.org/cms/attachment/f4002765-2864-4c75-bd5c-d9dd55018904/rth212674-fig-0003-m_lrg.jpg)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis
![Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile](https://www.researchgate.net/publication/370260615/figure/fig1/AS:11431281204687657@1699930400813/The-total-diagnostic-interval-between-different-age-groups-a-tumour-locations-b_Q320.jpg)
Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile
![A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40262-017-0616-3/MediaObjects/40262_2017_616_Fig6_HTML.gif)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - ScienceDirect Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S2475037922011657-rth212674-fig-0002-m.jpg)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - ScienceDirect
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis](https://www.rpthjournal.org/cms/asset/ca538398-db04-4bea-92f5-3d501cb20f77/rth212674-fig-0001-m.jpg)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Research and Practice in Thrombosis and Haemostasis
![PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A](https://www.researchgate.net/publication/304814489/figure/tbl1/AS:668713598611462@1536445154221/Outcomes-for-BAY-81-8973-first-6-month-vs-turoctocog-alfa_Q320.jpg)
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
![Andreas TIEDE | Professor (Full) | MD, PhD | Hannover Medical School, Hannover | MHH | Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation | Research profile Andreas TIEDE | Professor (Full) | MD, PhD | Hannover Medical School, Hannover | MHH | Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation | Research profile](https://www.researchgate.net/publication/347848024/figure/tbl1/AS:11431281209528544@1701800003057/Demographics-and-Baseline-Characteristics-of-Study-Population_Q320.jpg)
Andreas TIEDE | Professor (Full) | MD, PhD | Hannover Medical School, Hannover | MHH | Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation | Research profile
![A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40262-017-0616-3/MediaObjects/40262_2017_616_Fig4_HTML.gif)
A Pharmacometric Approach to Substitute for a Conventional Dose-Finding Study in Rare Diseases: Example of Phase III Dose Selection for Emicizumab in Hemophilia A | Clinical Pharmacokinetics
![Full article: Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial Full article: Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial](https://www.tandfonline.com/cms/asset/3f003b7b-afb2-4ee6-b056-3e696891e157/dtcr_a_12180937_f0001_b.jpg)
Full article: Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial
![Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis](https://www.rpthjournal.org/cms/attachment/c98587e2-f675-4575-acb5-c773689ac647/rth212760-fig-0002-m_lrg.jpg)
Managing surgery in hemophilia with recombinant factor VIII Fc and factor IX Fc: Data on safety and effectiveness from phase 3 pivotal studies - Research and Practice in Thrombosis and Haemostasis
![Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in](https://onlinelibrary.wiley.com/cms/asset/bbbe74fd-e115-47fa-b3a3-7e51a41b8368/rth2.v6.2.cover.jpg?trick=1701200479387)
Turoctocog alfa pegol (N8‐GP) in severe hemophilia A: Long‐term safety and efficacy in previously treated patients of all ages in the pathfinder8 study - Lentz - 2022 - Research and Practice in
![PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A](https://www.researchgate.net/publication/304814489/figure/fig1/AS:381313644285952@1467923665175/ABRs-for-BAY-81-8973-1-year-vs-rAHF-PFM-Note-Data-from-Valentino-et-al-17_Q320.jpg)
PDF) Matching-adjusted indirect comparisons of efficacy of BAY 81-8973 vs two recombinant factor VIII for the prophylactic treatment of severe hemophilia A
![Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile](https://www.researchgate.net/publication/376476947/figure/tbl1/AS:11431281211717403@1702492118429/Patient-characteristics_Q320.jpg)
Dragana JANIC | MD PhD Professor | University Children's Hospital, Belgrade, Serbia, Belgrade | Hematology and Oncology | Research profile
![PDF) Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey PDF) Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey](https://i1.rgstatic.net/publication/376043753_Real-World_Experience_of_People_with_Hemophilia_A_Receiving_Turoctocog_Alfa_Pegol_N8-GP_Results_from_a_Patient_Experience_Survey/links/656818e8ce88b870311fc3cc/largepreview.png)